GeorgeRSimonMD

Executive Medical Director and Dept. Chair Moffitt-AdventHealth Joint Clinical Research Unit Professor of Medicine and Oncology H Lee Moffitt Cancer Center & USF Morsani School of Medicine

Join to view full profile

Dr. Simon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Simon's full profile

Already have an account?

Office
380 Celebration Pl
Fl 2
Celebration, FL 34747
Phone+1 843-792-1414

Fax+1 407-303-4803

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 1992 - 1997
Saint Joseph HospitalResidency, Internal Medicine, 1993 - 1995
Christian Medical College LudhianaClass of 1986

Certifications & Licensure

FL State Medical License 2000 - 2026
OH State Medical License 2024 - 2026
OK State Medical License 2020 - 2021
TX State Medical License 2012 - 2021
SC State Medical License 2010 - 2013
PA State Medical License 2008 - 2010
CO State Medical License 1997 - 2009
AZ State Medical License 1997 - 1998
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Fellow (FACP) American College of Physicians, 2001
Join now to see all

Clinical Trials

Trial of Poor Performance Status Patients (ToPPS) Start of enrollment: 2009 Jun 01
Completed
Phase 2
Cisplatin and Pemetrexed With Radiation Followed by Lobectomy Start of enrollment: 2011 May 01
Terminated
Phase 1
A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2012 Jan 01
Withdrawn
Phase 2

Publications & Presentations

PubMed

1 citations
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.
Jeffrey M Clarke, George R Simon, Hirva Mamdani, Lin Gu, James E Herndon 2nd
Nature Communications. 2025-01-02
Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non-Small Cell Lung Cancer.
Chiharu Sako, Chong Duan, Kevin Maresca, Sean Kent, Taly Gilat Schmidt
JCO Clinical Cancer Informatics. 2024-12-01
Social determinants of health and variability in treatment for patients with early-stage Non-Small Cell Lung Cancer.
Molly Scannell Bryan, Xiaohan Hu, Monika A Izano, Hina Mohammed, Marianna Wicks
JNCI Cancer Spectrum. 2024-11-25

Press Mentions

Mesothelioma Treatment Program Expanding in Central FloridaSeptember 8th, 2021
Onc.AI Raises $6M Financing Round Co-Led by Blue Venture Fund and AccompliceDecember 3rd, 2020
Delivering a Cancer-Free Frontier During COVID-19September 4th, 2020
Join now to see all